Abstracts tagged "Biologicals"

Abstract Number: 2299 • ACR Convergence 2025
Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
Paula Estrada-Alarcón¹, Delia Reina², JUAN JOSE ALEGRE SANCHO³, Montserrat Roig Kim⁴, martí Aguilar-Coll⁵, Laia De Daniel Bisbe⁴, Aina Fabregat⁵, Monica Cubells⁵ and Javier Narváez⁶, ¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, ³Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁵Hospital Universitari de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To evaluate the real-world, long-term effectiveness of rituximab (RTX) as rescue therapy in patients with primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD).Methods: Multicentre observational…
Abstract Number: 1994 • ACR Convergence 2025
Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
Orrin Troum¹, John Botson², Afroz S. Mohammad³, Xiaoqing Yang⁴, Nathan Roe⁵, Supra Verma⁶ and Brian Lamoreaux⁷, ¹Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, ²Orthopedic Physicians Alaska, Anchorage, AK, ³Amgen Inc, Deerfield, ⁴Amgen, Seattle, WA, ⁵Horizon Therapeutics, Boise, ID, ⁶Horizon Therapeutics, Newport Beach, CA, ⁷Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase is approved for uncontrolled gout as 8-mg infusions admixed in 250 cc of normal saline over 120 minutes or more administered every 2…
Abstract Number: 1549 • ACR Convergence 2025
Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
Vasileios Kyttaris¹, Dan Persons², Gelareh Atefi³ and Mawuena Binka⁴, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Trio Health, Louisville, CO, ³AstraZeneca, Wilmington, DE, ⁴Former Employee of AstraZeneca, Wilmington, DE
Background/Purpose: Inflammatory arthritis is a cardinal manifestation of systemic lupus erythematosus (SLE), limiting joint mobility and adversely affecting quality of life.1 Joint activity in SLE…
Abstract Number: 1447 • ACR Convergence 2025
Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Ulrich Mrowietz¹, Laura Coates², Diamant Thaçi³, Mark Lebwohl⁴, Bardur Sigurgeirsson⁵, Richard B. Warren⁶, Richard G. Langley⁷, Andreas Clemens⁸, Cynthia Vizcaya⁸, Weibin Bao⁹, Kim Hoyt¹⁰, Lara Gómez¹¹ and Robert Bissonnette¹², ¹Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵University of Iceland, Faculty of Medicine, Department of Dermatology,, Reykjavik, Iceland, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Novartis Farmaceutica, Madrid, Spain, ¹²Innovaderm, Montreal, Québec, Canada
Background/Purpose: Secukinumab is a fully human monoclonal antibody that selectively inhibits interleukin-17A, demonstrating robust and sustained efficacy in moderate to severe psoriasis (PsO) and psoriatic…
Abstract Number: 1323 • ACR Convergence 2025
Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
Tatiana Lisitsyna¹, Anton Abramkin², Dmitry Veltishchev³, Sofia Kuzkina⁴, Anastasia Borisova², Vasily Ignatiev⁵, Mikhail Samsonov⁶ and Eugeny Nasonov², ¹Thromboinflammation Laboratory of the Department of Systemic Rheumatic Diseases V.A.Nasonova Research Institute of Rheumatology, Moskva, Russia, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁴R-Pharm, Moscow, Russia, ⁵"R-Pharm", JSC, Moscow, Russia, ⁶RPharm, Brussels, Belgium
Background/Purpose: Interleukin (IL)-6 plays an important role in the pathogenesis of depression in rheumatoid arthritis (RA) patients. IL-6 inhibitors used to treat patients with RA…
Abstract Number: 1090 • ACR Convergence 2025
Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Amelia Khoo and Anokhi Saklecha, Yale University, New Haven, CT
Background/Purpose: Rituximab, a monoclonal antibody which binds to the CD20 antigen of B cells, is used in the treatment of many rheumatologic conditions. Due to…
Abstract Number: 0588 • ACR Convergence 2025
The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
Casper Webers¹, AUGUSTA ORTOLAN², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Maastricht University Medical Centre, Maastricht, Netherlands, ²Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: In axial spondyloarthritis (axSpA), peripheral musculoskeletal manifestations (peripheral arthritis, enthesitis, dactylitis) are common and contribute to the burden of disease. Our objective was to…
Abstract Number: 0801 • ACR Convergence 2025
Achieving Sustained Lupus Low Disease Activity State and Remission With Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A post hoc Analysis From a Phase II Study
Eric Morand¹, Corine Gaillez², Stephen Oliver³, Swati Ghanshani⁴, Marilia Pozzobon⁵, Weibin Bao⁶ and Ed Vital⁷, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Novartis Pharma AG, Basel, Switzerland, Croissy Sur Seine, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Healthcare Private Limited, Hyderabad, India, Hyderabad, India, ⁵Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁷University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Ianalumab, a fully human monoclonal antibody against the B cell–activating factor receptor (BAFF-R), has a dual mechanism of action of B cell depletion through…
Abstract Number: 0479 • ACR Convergence 2025
Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Asim Khanfar¹, Omar Hamdan², Shiamak Cooper³, Sanjana Thimmannagari¹ and Anthony Ocon⁴, ¹Rochester General Hospital, Rochester, NY, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Irondequoit, NY, ⁴Rochester Regional Health, Fairport, NY
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are immunomodulatory agents commonly used in the treatment of rheumatoid arthritis and COVID-19. Prior studies have implicated…
Abstract Number: 0153 • ACR Convergence 2025
Patient Experience and Implementation of an Electronic Patient-Reported Outcome Measures (ePROM) System for Remote Monitoring in BIOBADASER
Isabel Castrejón Fernández¹, Lucia Otero², Antonio Mera-Valera³, Alicia Garcia⁴, Silvia Gomez-Sabater⁵, Raquel Martín-Domenech⁶, Jose Alvaro-Gracia⁷, Juan Camilo Sarmiento-Monroy⁸, Beatriz Ventosa² and Fernando Sánchez-Alonso⁹, ¹Department of Rheumatology. Hospital General Universitario Gregorio Marañon. IiSGM. Universidad Complutense Madrid, Madrid, Spain, ²Spanish Society of Rheumatology, Madrid, Spain, ³H. Clínico Universitario de Santiago, Santiago de Compostela, ⁴Rheumatologist, La Laguna, Spain, ⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ⁶H. Universitario de Elda, Elda, Spain, ⁷Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Department of Rheumatology, Hospital General Universitario Gregorio Marañón and Faculty of Medicine, Complutense University of Madrid, Madrid, Spain, ⁸Hospital Clínic Barcelona, Barcelona, Spain, ⁹Sociedad Española de Reumatología, Madrid, Spain
Background/Purpose: Patient-Reported Outcome Measures (PROMs) are integral to shared decision-making and quality improvement in rheumatology. They are recommended for monitoring treatment response, assessing quality of…
Abstract Number: 2662 • ACR Convergence 2025
Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease
Gregory McDermott¹, Daniel Solomon², Jeffrey Sparks³ and Rishi Desai³, ¹Brigham and Women's Hospital, Brookline, MA, ²Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: RA-ILD is associated with high mortality, but the optimal treatment approach is unclear. While immunosuppressants may treat inflammatory components of ILD, there are concerns…
Abstract Number: 2453 • ACR Convergence 2025
Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE
Maral DerSarkissian¹, Yan Chen¹, Ariel Chao¹, Shumin Rui¹, Bronwyn Moore², Karen Worley³, Daniel Moldaver⁴, Jeffrey J. Ellis³ and Aarat M Patel⁵, ¹Analysis Group, Los Angeles, CA, ²Analysis Group, Montreal, QC, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ⁵GSK, US Medical Affairs, Durham, NC
Background/Purpose: LN develops in ~40% of patients with SLE and is associated with increased risk of morbidity, including end-stage kidney disease, and mortality. Belimumab, a…
Abstract Number: 2300 • ACR Convergence 2025
Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
sandrine jousse¹, Valerie Devauchelle², baptiste quere¹, Divi Cornec³, Caroline Denis⁴, Thierry MARHADOUR¹, Alice Tison¹, Patricia Baley⁴, Alain SARAUX⁵, Noemi Giglioli⁶, CAROLE SIPS⁶, Shuqi Chen⁷, Rainer Hillenbrand⁶, Richard Siegel⁸, Wolfgang Hueber⁹, Claire Bonal⁶ and Didier Laurent⁶, ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²UBO, Brest, France, ³LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁴CHU Brest, Brest, France, Brest, France, ⁵CHU Brest, Brest, France, ⁶Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁷China Novartis Institutes for BioMedical Research, Shanghai, China, Shangai, China (People's Republic), ⁸Novartis Biomedical Research, Basel, Switzerland, ⁹Novartis Pharmaceuticals, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered, fully human IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions through dual mechanism of…
Abstract Number: 1992 • ACR Convergence 2025
Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
Vinicius Domingues¹, Alexis Woods², Xiaoqing Yang³, Brian Lamoreaux⁴ and Michael Weinblatt⁵, ¹Rheumatology, Allergy, Asthma & Arthritis Center, Daytona beach, FL, ²Amgen, Detroit, MI, ³Amgen, Seattle, WA, ⁴Amgen, Inc., Deerfield, IL, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Methotrexate (MTX) coadministered with pegloticase attenuates anti-drug antibody formation, leading to higher response rates and markedly reduced infusion reaction risk compared with pegloticase +…
Abstract Number: 1548 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice
Vanesa Calvo-Río¹, Carmen Secada-Gómez¹, Miriam Retuerto Guerrero², Judit Font-Urgelles³, Ivette Casafont-Solé³, Adrián Mayo-Juanatey⁴, Juan José Alegre-Sancho⁵, DALIFER FREITES⁶, Cristina Hormigos Martin⁷, Noemí Garrido⁸, GUILLERMO GONZALEZ ARRIBAS⁹, Juan Roberto Miguelez Sanchez¹⁰, Andrea García-Valle¹¹, Marta Ibañez¹², Fernando Lozano Morillo¹³, Ángel García Manzanares¹⁴, Sebastián Sandoval-Moreno¹⁵, Josefina Cortés-Hernández¹⁶, Deseada Palma-Sanchez¹⁷, LETICIA LOJO-OLIVEIRA¹⁸, Evelin Cervantes¹⁹, Paz Collado Ramos²⁰, cristina arciniega Larios²¹, Luis Sala²², Eztizen Labrador-Sánchez²³, Cilia Peralta-Ginés²⁴, Nahia Plaza-Aulestia²⁵, Irati Urionaguena Onaindia²⁶, Miguel Medina Malone²⁷, Jose Rosas Gómez de Salazar²⁸, Montserrat Corteguera²⁹, Laura Cebrian³⁰, Fred Anton Pages³¹, Jose Ramón Lamua-Riazuelo³², María Dolores Fábregas Canales³³, María José Alados Hernández³⁴, Marta Garijo Bufort³⁵, Anna Pamies³⁶, Luis Sarabia³⁷, Rodrigo Aguirre-del-Pino³⁸, José Ángel Cabezas Lefler³⁹, alvaro seijas³⁸, Carmen Carrasco-Cubero⁴⁰, Ana López-Cerón Cofiño⁴¹, Vera Ortiz-Santamaria⁴², Santos Castañeda⁴³, Maria Laino⁴⁴, Carmen Ordás Calvo⁴⁵, Celia arconada⁴⁶, ana Urruticoechea-Arana⁴⁷, Blanca Garcia-Magallon⁴⁸, Ana Valeria Acosta Alfaro⁴⁹, Samuel Leal Rodriguez⁵⁰, Marina Salido Olivares⁷, Patricia Lavilla Villar⁵¹, Anahy Maria Brandy³, Inmaculada Ros Vilamajo⁵², Alvaro García Martos⁵³, Berta Magallares⁵⁴, Guillen Sada Urmeneta⁵⁵, Cristina Córdoba Martín⁵⁶, Elena Riera Alonso⁵⁷, Carmen Bejerano-Herreria⁵⁸ and Ricardo Blanco,<58, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁵Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁹Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁰Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain, ¹¹Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ¹³Hospital Central de La Defensa Gómez Ulla, Madrid, Madrid, Spain, ¹⁴Hospital Universitario de Torrevieja, Alicante, Spain, ¹⁵Hospital Universitario Vall D'Hebron, Barcelona, Spain, ¹⁶Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ¹⁷Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁹Hospital Provincial de Pontevedra, Pontevedra, Spain, ²⁰Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, ²¹Hospital de Mérida, Badajoz, Spain, ²²Hospital Universitario de Torrejón, Madrid, Spain, ²³Hospital General de La Rioja, Logroño, Spain, ²⁴Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁵Hospital Galdakao, Vizcaya, Spain, ²⁶Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, ²⁷Hospital de Calahorra, Calahorra, Spain, ²⁸Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁹Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁰Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ³¹Hospital General de Segovia, Segovia, Spain, ³²Hospital Universitario del Henares, Madrid, Spain, ³³Hospital de Barbastro, Huesca, Spain, ³⁴Hospital Universitario Puerta del Mar, Cadiz, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital Verge de la Cinta, Tortosa, Tarragona, Spain, ³⁷Complejo Hospitalario de Jaén, Jaén, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Complejo Asistencial de Zamora, Zamora, Spain, ⁴⁰Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁴¹Hospital Santa Bárbara, Soria, Spain, ⁴²Hospital General de Granollers, Barcelona, Spain, ⁴³Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁴⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁴⁵Hospital Universitario de Cabueñes, Gijón, Spain, ⁴⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁴⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴⁸Rheumatology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴⁹Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ⁵⁰Hospital Universitario La Fe, Valencia, Valencia, Spain, ⁵¹Hospital General de Villalba, Collado Villalba, Madrid, Spain, ⁵²Hospital Son Llàtzer, Palma de Mallorca, Spain, ⁵³Hospital del Tajo, Aranjuez, Madrid, Spain, ⁵⁴Hospital de Sant Pau, Barcelona, Spain, ⁵⁵Rheumatology, Hospital Reina Sofía, Tudela, Spain, ⁵⁶Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain, ⁵⁷Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁵⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.

Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1). ANI was approved by Spanish authorities…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].